Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
暂无分享,去创建一个
G. Ciliberto | A. Paradiso | F. Baldanti | G. Apolone | C. Agrati | M. Inglese | M. Costantini | P. Zinzani | E. Cimini | C. Castilletti | A. Sacchi | R. Casetti | V. Bordoni | F. Tagliavini | T. Lazzarotto | F. Merli | P. Zinzani | A. Bertuzzi | G. Piaggio | L. Dagna | M. Rescigno | F. Locatelli | S. Di Cosimo | C. Carlo-Stella | R. Mantegazza | C. Selmi | A. Uccelli | C. Montecucco | F. Valzania | F. Baggi | D. Giannarelli | C. Tresoldi | F. Ciceri | M. Pantaleo | S. Monti | D. Goletti | E. Girardi | A. Laroni | A. Mantovani | A. Ceribelli | R. Carsetti | C. Salvarani | F. Bonifazi | C. Genova | S. Croci | Michela Lizier | R. Mortarini | A. Mengarelli | C. Quintarelli | R. Divella | P. Corradini | G. Grassi | G. Fornasa | S. Damian | F. Pimpinelli | M. Filippi | P. Pronzato | M. De Santis | D. Fenoglio | N. Silvestris | M. Stanghellini | I. Poirè | E. Azzolini | M. D. Dal Bello | D. Mariotti | F. Colavita | D. Lapa | G. Matusali | S. Meschi | C. Lapucci | F. Marchesi | C. Pozzi | M. Catanoso | Monica Guberti | C. Mandoj | A. Tufaro | V. Garrisi | S. Notari | M. Fusconi | L. Germagnoli | V. Stefoni | Carmine Pinto | F. Motta | I. Cassaniti | I. Pulice | E. Turola | D. Graceffa | S. Delcuratolo | E. Papa | M. Lupo-Stanghellini | S. Gili | A. Bruno | V. Sinno | F. Locatelli | Federica Bortone | Massimo Francalancia | Eleonora Tartaglia | A. Morrone | S. Trinca | Laura Conti | Aurora Bettini | Giulia Gramigna | V. Marasco | Filippo G. de Braud | Arianna Belvedere | S. Leone | Giovanni Alberto Massimo Nicola Chiara Giovanni Fabio Genna Apolone Mantovani Costantini Silvestris | Flavia Cristofanelli | Enzo Puro | Marika Rubino | Francesca Ogliari | Gloria Catalano | Rosamaria Nitti | Giancarlo Paoletti e Gabriele Minuti | C. Miggiano | Mariana Miano | Alessandro Barberini | Rinaldi Elena | Silvia Corazza | F. D. de Braud | M. Guberti
[1] Christina C. Chang,et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.
[2] Heidi Ledford. How severe are Omicron infections? , 2021, Nature.
[3] G. Screaton,et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum , 2021, The Lancet.
[4] F. Baldanti,et al. Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant , 2021, Microorganisms.
[5] I. Wolf,et al. Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer , 2021, The Lancet Oncology.
[6] C. Agrati,et al. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies , 2021, Neurology.
[7] J. Gottenberg,et al. Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab , 2021, The Lancet Rheumatology.
[8] A. Wheatley,et al. Boosting immunity to COVID-19 vaccines , 2021, Nature Medicine.
[9] F. Baldanti,et al. Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis , 2021, Rheumatology.
[10] G. Apolone,et al. T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies , 2021, British journal of haematology.
[11] B. LaFleur,et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors , 2021, Nature Medicine.
[12] J. Mascola,et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.
[13] Michael J. Ryan,et al. Considerations in boosting COVID-19 vaccine immune responses , 2021, The Lancet.
[14] F. Baldanti,et al. Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study , 2021, Clinical Microbiology and Infection.
[15] P. Klenerman,et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern , 2021, Nature Communications.
[16] G. Shefer,et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma , 2021, Blood Advances.
[17] G. Ciliberto,et al. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial , 2021, Frontiers in Immunology.
[18] B. Mizrahi,et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.
[19] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.
[20] L. Pagano,et al. COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies , 2021, British journal of haematology.
[21] A. Reiner-Benaim,et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer , 2021, Annals of Oncology.
[22] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[23] F. Hernandez-Ilizaliturri,et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies , 2021, Blood.
[24] J. Izopet,et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.
[25] C. Agrati,et al. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine , 2021, Microorganisms.
[26] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[27] E. Wherry,et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.
[28] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[29] G. Ciliberto,et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution , 2021, Journal of Hematology & Oncology.
[30] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[31] P. Kellam,et al. T cell response to SARS-CoV-2 infection in humans: A systematic review , 2021, PloS one.
[32] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[33] C. Dutertre,et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , 2020, bioRxiv.
[34] M. Sormani,et al. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments , 2020, Multiple sclerosis.
[35] G. Curigliano,et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies , 2020, European Journal of Cancer.
[36] A. Vannelli,et al. Comment on “Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano” , 2020, Tumori.
[37] G. Corrao,et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.
[38] Zeyu Chen,et al. T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.
[39] M. Massari,et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study , 2020, Annals of the Rheumatic Diseases.
[40] G. Salles,et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience , 2017, Advances in Therapy.
[41] N. Frey,et al. Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin’s Lymphoma (NHL) Patients. , 2007 .